DC Chemicals · Product datasheet

Fatostatin — Datasheet

CAT. NO. DC10213

Product page and current package options

ParameterValue
Chemical NameFatostatin HBr
CAS No.298197-04-3
SynonymsFatostatin A Hydrobromide;fatostatin;Fatostatin (hydrobromide);Fatostatin A;2-(2-propylpyridin-4-yl)-4-p-tolylthiazole hydrobromide;FATOSTATIN (2-(2-PROPYLPYRIDIN-4-YL)-4-(P-TOLYL)THIAZOLE);25B11 hydrobromide;4-[4-(4-methylphenyl)-2-thiazolyl]-2-propylpyridine hydrobromide;Fatostatin HBr;Fatostatin A HBr;Fatostatin Hydrobromide;2-(2-Propylpyridin-4-yl)-4-(p-tolyl)thiazole hydrobromide;SMR000221636;2-Propyl-4-(4-p-tolyl-thiazol-2-yl)-pyridine;MLS000332366;C18H19BrN2S;MLS003593148;BCP20908;s8284;Fatostatin A Hydrobromide;Fatostatin A;AX8289397;4-[4-(4-Methylphenyl)-2-thiazolyl]-2-propylpyr
FormulaC18H19BrN2S
M.Wt375.328
SMILESBr[H].S1C([H])=C(C2C([H])=C([H])C(C([H])([H])[H])=C([H])C=2[H])N=C1C1C([H])=C([H])N=C(C=1[H])C([H])([H])C([H])([H])C([H])([H])[H]
Purity>98%
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

Fatostatin hydrobromide (125B11 hydrobromide), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. Fatostatin hydrobromide binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin hydrobromide decreases the transcription of lipogenic genes in cells. Fatostatin hydrobromide possesses antitumor properties, and lowers hyperglycemia in ob/ob mice[1][2].

In Vitro

Fatostatin hydrobromide (125B11 hydrobromide) (0.1-1 μM; 3 days) inhibits the androgen-independent prostate cancer cell proliferation (IC50=0.1 μM) in an independent of the known IGF1-signaling pathway. Fatostatin hydrobromide inhibits insulin-induced adipogenesis of 3T3-L1 cells[1]. Cell Proliferation Assay[1] Cell Line: DU-145 cells Concentration: 0.1, 1 μM Incubation Time: 3 days Result: Impaired the IGF1-induced growth at an IC50 of 0.1 μM.

In Vivo

Fatostatin hydrobromide (125B11 hydrobromide) (30 mg/kg; 150 mL; i.p.; daily for 28 days) reduces adiposity, ameliorates fatty liver by reducing triglyceride (TG) storage, and lowers hyperglycemia in ob/ob mice[2]. Animal Model: Four-to-five-week-old homozygous male obese (ob/ob) mice (C57BL/6J)[2] Dosage: 30 mg/kg; 150 mL Administration: i.p. injection; daily for 28 days Result: Blocked increases in body weight, blood glucose, and hepatic fat accumulation in obese ob/ob mice, even under uncontrolled food intake.

References & source

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.

Cart

Request quotation